Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephen Miller
Northwestern University at Chicago, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cour Pharmaceutical Development Company, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This project will test whether two FDA-approved drugs, digoxin and miconazole, alone and in combination with PLGA nanoparticle tolerance-based immunoregulatory therapies, promote remyelination in mouse models of multiple sclerosis (MS). The underlying PLGA nanoparticle technology is licensed to and being commercialized by Cour Pharmaceuticals, a company that Miller has a financial interest in. Should this project be successful, it could be of benefit to Cour, thus creating a perceived conflict of interest that should be managed.
Combining Immune Tolerance and Myelin Repair Therapy in T cell-driven MS Models
The proposed studies will investigate effects of the FDA-approved drugs, digoxin and miconazole, that we recently demonstrated to promote endogenous myelin repair by stimulating oligodendrocyte progenitor cell (OPC) expansion and/or differentiation, alone and in combination with PLG nanoparticle tolerance-based immunoregulatory therapies in mouse models of MS: chronic and relapsing remitting CD4+ T cell-mediated EAE driven by autoreactive myelin-specific Th1/17 cells. Digoxin and miconazole are orally available and cross the blood-brain barrier. The proposed pre-clinical studies will hopefully lead to development of a robust screening procedure for validating the efficacy of potential myelin repair drugs in vivo under inflammatory (EAE model) conditions as well as demonstrate a novel and safe targeted combinatorial therapeutic approach translatable into an effective MS disease modifying therapy.
Filed on March 13, 2019.
Tell us what you know about Stephen Miller's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stephen Miller filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stephen Miller | Northwestern University at Chicago | Conflict of Interest | Cour Pharmaceutical Development Company, Inc. | $20,000 - $39,999 |
| Stephen Miller | Northwestern University at Chicago | Conflict of Interest | Cour Pharmaceutical Development Company, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.